← Back to Patent Explorer
US4092408A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for solid phase immunological assay of antigen

Assignee: EIDP Inc
•
Filing: 1975-08-28
•
Granted: 1978-05-30
•
Expires: 1995-08-28
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An improved solid-phase radioimmunological assay method for assay of an antigen in a biological fluid, e.g., blood plasma, by use of a solid phase polymeric substrate on which is adsorbed in solid phase an antibody composite layer, comprising a solid phase precoat of an anti-antibody (Ab 2 ) (i.e., an antibody to an animal blood serum and sometimes referred to as a second antibody) bound to said substrate and a solid phase antibody Ab specific to said antigen (sometimes referred to as a primary antibody) immunologically bound to said anti-antibody precoat. The biological fluid to be tested, containing the antigen and radioactive labelled antigen, is contacted with the antibody surface of the composite layer to immunologically bind antigen and radioactive labelled antigen to the solid phase Ab surface, whereupon the quantity of antigen in the biological fluid is determined by measuring the radioactivity of the composite layer and substrate or of the remaining biological fluid containing unbound antigen and unbound radioactive labelled antigen. An improved method for making as an article of manufacture solid phase antibody (Ab) for radioimmunological assay of antigen by first adsorbing Ab 2 from its serum on a solid substrate to produce a solid Ab 2 precoat and then reacting the Ab 2 precoat with Ab in its antiserum to form a solid phase Ab coating on the Ab 2 precoat whereby an effective, efficient, reproduceable and stable solid phase antibody Ab for assay of antigen is obtained with a substantial decrease in the amount of Ab required. The terms coating, precoating, coat and coating do not necessarily mean continuous or complete coat or coating of the underlying surface but, instead, include continuous and non-continuous coatings.

Inventors

  • 👤 Gerald J. Litt

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 18:24
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/543; G01N33/544; Y; Y10; Y10S; Y10S436/00; Y10S436/804; Y10S436/807; Y10S436/808; Y10S436/81; Y10S436/815; Y10S436/817

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 128 words
An improved method for solid phase immunological assay of an antigen comprising (a) contacting anti-antiserum containing anti-antibody with a substrate surface capable of adsorbing said anti-antibody to form solid phase anti-antibody bound to said substrate surface (b) incubating said solid phase anti-antibody while bound to said substrate with antiserum containing antibody to form solid phase antibody bound to said solid phase anti-antibody (c) incubating said solid phase antibody, while bound to said solid phase anti-antibody and said substrate, with a solution containing antigen specific to said antibody and the same antigen labelled with a tracer, to form solid phase antigen and solid phase tracer-labelled antigen bound to said solid phase antibody and (d) measuring the tracer activity either of said solid phase antibody-anti-antibody-substrate or of the remaining solution.
Claim 2
Dependent Claim 128 words
An improved method for solid phase immunological assay of an antigen comprising (a) contacting anti-antiserum containing anti-antibody with a substrate surface capable of adsorbing said anti-antibody to form solid phase anti-antibody bound to said substrate surface (b) incubating said solid phase anti-antibody while bound to said substrate with antiserum containing antibody to form solid phase antibody bound to said solid phase anti-antibody (c) incubating said solid phase antibody, while bound to said solid phase anti-antibody and said substrate, with a solution containing antigen specific to said antibody and the same antigen labelled with a tracer, to form solid phase antigen and solid phase tracer-labelled antigen bound to said solid phase antibody and (d) measuring the tracer activity either of said solid phase antibody-anti-antibody-substrate or of the remaining solution.
Claim 3
Dependent Claim 21 words
The method according to claim 1 wherein said immunological assay is a radioimmunological assay and said tracer is a radioactive substance.
Claim 4
Dependent Claim 24 words
The method according to claim 2 wherein said antigen is a digoxin antigen and said antiserum is diluted to between about 1:100,000 and 1:1000000.
Claim 5
Dependent Claim 17 words
A method according to claim 2 where said anti-antiserum is diluted to between about 1:100 and 1:10000.
Claim 6
Dependent Claim 12 words
A method according to claim 2 wherein the substrate is a polymer.
Claim 7
Dependent Claim 36 words
A method according to claim 5 wherein said polymer is selected from the group consisting of a polymer of styrene, a polymer of ethylene, a polymer of propylene and an acrylic polymer and a cellulosic polymer.
Claim 8
Dependent Claim 16 words
A method according to claim 6 wherein said substrate is a polypropylene or a polystyrene tube.
Claim 9
Dependent Claim 11 words
A method according to claim 2 wherein said antiserum is unpurified.
Claim 10
Dependent Claim 13 words
A method according to claim 2 wherein said radioactive substance is 125 I.
Claim 11
Dependent Claim 53 words
As an article of manufacture, a solid phase radioimmunological assay kit comprising a plurality of tubes having an internal substrate surface having bound thereto solid phase anti-antibody to which is bound solid phase antibody and a plurality of vials containing radioactive labelled antigen specific to said antibody, antigen standards, and a buffering solution.
Claim 12
Dependent Claim 53 words
As an article of manufacture, a solid phase radioimmunological assay kit comprising a plurality of tubes having an internal substrate surface having bound thereto solid phase anti-antibody to which is bound solid phase antibody and a plurality of vials containing radioactive labelled antigen specific to said antibody, antigen standards, and a buffering solution.

References Cited (Backward Citations)

US3896217A Cited
US3904367A Cited
US3876504A Cited
US3979509A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-05-29 1981-11-28 1982-05-30 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-05-29 1985-11-28 1986-05-30 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-05-29 1989-11-28 1990-05-30 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag